English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Introduction Cancer is the most prevalent disease worldwide, causing a major impact on society. Early detection and monitorization of the tumour can provide a more effective treatment. Point-of-care (POC) testing allows the patient to have a handheld test that gives the results rapidly. No expertise or special knowledge is required which is vital namely when carried out in low-resource areas. Recent studies analysed established and emerging biomarkers and how to incorporate them into POC devices, but a systematic review reporting the existing POC platforms for cancer is still not available. Objectives This systematic review aims to report current and recent advances for point-of-care testing in cancer. Methodology A literature review was conducted through research in the databases “PubMed” and “B-On” for relevant reviews published in the last ten years, using the keywords “Point-of-care testing” AND “Cancer” AND “Rapid Test” AND “Cancer detection”. Results In 2015 there were eight commercially available POC tests for prostate, bladder, colorectal, cervical, HPV-causing head and neck cancer, liver, breast and lung cancer. After 2018 a small number of POC devices were tested in screening programs and multicentric studies, and more recently, promising novel POC prototypes for early detection of cancer, namely a 3D prototype micro device for multiple singleplex RNA expression analysis in liver cancer and a POC microscopy prototype for digital diagnostics of breast cancer lymph node metastases, with potential to be used in resource-limited settings. Conclusion The use of POC testing can deliver accurate, fast results, and in the case of cancer it is no exception, contributing to the progression of treatment and reduction in cancer-related deaths. In low-resource settings a POC test is fundamental and it should be simple and low-cost. But there are limitations in the tests which is a challenge for improvement and investigation in the future.

Current Point-of-Care testing in cancer and future perspectives: a systematic review